Ace inhibitors in ckd
Pro Research Analysisby 
Searched over 200M research papers
ACE Inhibitors in Chronic Kidney Disease (CKD)
Introduction to ACE Inhibitors in CKD
Angiotensin-converting enzyme (ACE) inhibitors are a cornerstone in the management of chronic kidney disease (CKD). They are primarily used to control blood pressure and reduce proteinuria, which are critical factors in slowing the progression of CKD and preventing cardiovascular events.
Efficacy of ACE Inhibitors in CKD
Kidney Failure and Cardiovascular Outcomes
ACE inhibitors have been shown to significantly reduce the risk of kidney failure and major cardiovascular events in patients with CKD. A comprehensive Bayesian network meta-analysis of 119 randomized controlled trials involving 64,768 patients demonstrated that ACE inhibitors reduced the odds of kidney failure by 39% compared to placebo and by 35% compared to other active controls . Additionally, ACE inhibitors were associated with a reduction in major cardiovascular events and all-cause mortality, making them a superior choice over angiotensin II receptor blockers (ARBs) in this patient population Xie2016Zhang2020.
Non-Dialysis CKD Stages 3-5
In patients with non-dialysis CKD stages 3-5, ACE inhibitors have shown significant benefits. A network meta-analysis of 44 randomized clinical trials with 42,319 patients found that ACE inhibitors significantly decreased the odds of kidney events, cardiovascular events, cardiovascular death, and all-cause death compared to placebo . This analysis highlighted the superior protective effects of ACE inhibitors on kidney and cardiovascular outcomes, even though they increased the risk of hyperkalemia and cough .
Safety Concerns and Adverse Effects
Hyperkalemia and Renal Function Impairment
The main adverse effects of ACE inhibitors include hyperkalemia, renal function impairment, and hypotension. These effects are primarily due to their interaction with the renin-angiotensin-aldosterone system (RAAS) and volume depletion . Strategies to mitigate these risks include reducing dietary sodium intake and avoiding dual RAAS blockade, which has been associated with increased safety concerns .
Discontinuation Due to Adverse Effects
Despite their benefits, ACE inhibitors are often underused due to concerns about hyperkalemia, acute kidney injury (AKI), and hospitalization. A joint analysis of the CREDENCE and DAPA-CKD trials found that the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the relative risk of discontinuation of ACE inhibitors and ARBs by 15%, suggesting that SGLT2 inhibitors may facilitate the persistent use of RAAS blockade in CKD patients .
Comparative Superiority of ACE Inhibitors Over ARBs
Head-to-Head Comparisons
Although direct head-to-head trials comparing ACE inhibitors and ARBs in CKD are limited, network meta-analyses suggest that ACE inhibitors may be superior to ARBs in reducing kidney failure, cardiovascular death, and all-cause mortality Xie2016Mavridis2016. This has led to recommendations that ACE inhibitors should be the first choice for treatment in CKD patients, particularly those with diabetic kidney disease .
Advanced CKD and ACE Inhibitor Withdrawal
STOP-ACEi Trial
The STOP-ACEi trial is investigating whether the withdrawal of ACE inhibitors or ARBs in patients with advanced CKD (stages 4 or 5) can stabilize or improve renal function. Preliminary findings suggest that discontinuation of these treatments may benefit renal function without increasing cardiovascular events, but the final results are awaited to provide definitive guidance Bhandari2015Ahmed2016.
Conclusion
ACE inhibitors play a crucial role in managing CKD by reducing the risk of kidney failure and cardiovascular events. Despite their associated risks, such as hyperkalemia and renal function impairment, their benefits often outweigh these concerns. Comparative studies indicate that ACE inhibitors may be superior to ARBs, making them the preferred choice in many CKD patients. Ongoing research, such as the STOP-ACEi trial, will further elucidate their role in advanced CKD.
Sources and full results
Most relevant research papers on this topic